Gilgamesh Pharma
Also known as: Gilgamesh Pharmaceuticals, Gilgamesh Pharma Inc.
Gilgamesh Pharma Inc. is the post-spinoff successor of Gilgamesh Pharmaceuticals, created in October 2025 when AbbVie acquired Gilgamesh's lead asset bretisilocin (GM-2505) for up to $1.2B. Launched with over $100M in funding and retaining the original team, Gilgamesh Pharma is advancing a pipeline of rapid-acting, durable psychiatric therapeutics including blixeprodil (GM-1020), a first-in-class oral NMDA receptor antagonist. Positive Phase 2a data for blixeprodil were announced January 6, 2026, and late-stage development is planned for 2026. The company also retains an ongoing AbbVie collaboration on non-hallucinogenic neuroplastogens.
Drug Pipeline
3Blixeprodil (GM-1020)
Major depressive disorder (MDD). First-in-class oral NMDA receptor antagonist (not hallucinogenic). Phase 2a (n=46): Part A single-dose RCT (140 mg) + Part B multi-dose extension (140 vs 210 mg twice weekly x2 weeks + 28-day follow-up). Positive topline results announced Jan 6, 2026: rapid, robust, and durable antidepressant effects. Entering late-stage development 2026.
GM-3009
IbogaineOUD, PTSD, TBI. Cardio-safe ibogaine analog with improved cardiac safety and efficacy profiles relative to ibogaine. Preclinical stage.
M1/M4 Muscarinic Agonist
Schizophrenia. Muscarinic M1/M4 receptor agonist programme. Preclinical stage.
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Phase II
- HQ
- New York, NY, USA, United States
- Website
- Visit